Sign in

    Blair Cohen

    Research Analyst at H.C. Wainwright

    Blair Cohen's questions to Kezar Life Sciences (KZR) leadership

    Blair Cohen's questions to Kezar Life Sciences (KZR) leadership • Q2 2020

    Question

    Blair Cohen of H.C. Wainwright inquired about the timeline for the next update from the Stage 1b MISSION study, the impact of COVID-19 on the PRESIDIO trial, the company's cash runway after its recent offering, and the planned initiation and design for the KZR-261 study.

    Answer

    Chief Medical Officer Noreen Henig projected an interim MISSION study update by the end of 2020, with a follow-up in H1 2021. She also noted the PRESIDIO trial timeline is now extended to mid-2022 due to COVID-19, but data integrity should be unaffected. CFO Marc Belsky confirmed the cash runway extends through 2023. President & CSO Christopher Kirk stated the IND for KZR-261 is targeted for Q1 2021, with a trial in solid tumors to begin shortly after.

    Ask Fintool Equity Research AI

    Blair Cohen's questions to Kezar Life Sciences (KZR) leadership • Q2 2020

    Question

    Blair Cohen of H.C. Wainwright inquired about the timeline for the next MISSION Phase Ib study update, the impact of COVID-19 on the PRESIDIO trial, the company's cash runway, and the development plan for KZR-261.

    Answer

    Chief Medical Officer Noreen Henig projected an interim MISSION update by year-end 2020 and noted the PRESIDIO trial completion is now expected in mid-2022 due to COVID-19, with no impact on data integrity. Chief Financial Officer Marc Belsky confirmed the company's cash runway extends through 2023. Chief Scientific Officer Christopher Kirk stated the KZR-261 IND filing is planned for Q1 2021.

    Ask Fintool Equity Research AI